Recent Updates
Recently added Catalysts
ALT Negative Sentiment Score: 20/100

Altimmune, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit

Key Takeaway: A securities fraud lawsuit has been filed against Altimmune, Inc. and its executives, following a drop in stock value attributed to poor tolerability of its GLP-1 drug and the diminished likelihood of forming a strategic partnership. Investors who lost money between December 01, 2023, and April 26, 2024, are encouraged to contact the legal firm Block & Leviton for potential recovery options. The lawsuit alleges that Altimmune misrepresented its capabilities related to the drug's commercial prospects. The deadline for investors to seek appointment as lead plaintiff is set for July 05, 2024.

Market Sentiment Analysis

CONCERNS & RISKS

  • Altimmune has faced a significant stock decline due to negative reports about its GLP-1 drug's tolerability.
  • A lawsuit has been filed alleging that Altimmune overstated its prospects for securing a strategic partner.
  • The stock fell further after a market analyst indicated that a partnership was increasingly unlikely.

Full Press Release Details

BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against Altimmune, Inc. (Nasdaq: ALT) and certain of its executives. Investors who have lost money in their Altimmune, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/alt.
What is this all about?
Altimmune stock fell on February 13, 2024, following publication of a report noting that Altimmune's GLP-1 drug had low tolerability and was unlikely to generate the partnership opportunities the company needed to succeed. Then, on April 29, market analyst Guggenheim noted that a partership looked "increasingly unlikely," again causing the stock to fall. The lawsuit alleges that the company overstated its prospects for finding a strategic partner for its GLP-1 drug.
Anyone who purchased Altimmune, Inc. common stock between December 01, 2023 and April 26, 2024 and has seen their shares fall may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What should you do next?
The deadline to seek appointment as lead plaintiff is July 05, 2024. A class has not yet been certified, and until a certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. If you've lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at cases@blockleviton.com, or by phone at (617) 398-5600.
If you have non-public information about Altimmune, Inc., you should consider assisting in our investigation or working with our attorneys to file a report with the Securities Exchange Commission under their whistleblower program. Whistleblowers who provide original information to the SEC may receive rewards of up to 30% of any successful recovery. For more information, contact Block & Leviton at cases@blockleviton.com or by phone at (617) 398-5600.
Why should you contact Block & Leviton?
Block & Leviton is widely regarded as one of the leading securities class action firms in the country. Our attorneys have recovered billions of dollars for defrauded investors and are dedicated to obtaining significant recoveries on behalf of our clients through active litigation in the federal courts across the country. Many of the nation's top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, call (617) 398-5600 or email cases@blockleviton.com with any questions.
This notice may constitute attorney advertising.
260 Franklin St., Suite 1860
Phone: (617) 398-5600

Tags

Frequently Asked Questions

What lawsuit was filed against Altimmune, Inc.?

A securities fraud lawsuit was filed against Altimmune and its executives.

Why did Altimmune's stock fall in early 2024?

The stock fell due to reports of low tolerability of its GLP-1 drug and partnership concerns.

Who can join the Altimmune lawsuit?

Investors who bought shares between December 1, 2023, and April 26, 2024, may join.

What should investors do if they lost money?

Contact Block & Leviton to explore recovery options for your losses.

What is the lead plaintiff deadline for the lawsuit?

The deadline to seek lead plaintiff status is July 5, 2024.

Last updated: May 8, 2024